+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: not found

      Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature.

      Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
      Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Granulocyte Colony-Stimulating Factor, therapeutic use, Humans, Infant, Male, Melioidosis, drug therapy, epidemiology, mortality, Middle Aged, Northern Territory, Prospective Studies, Risk Factors, Shock, Septic, Trimethoprim-Sulfamethoxazole Combination, Tropical Climate

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          In a prospective study of melioidosis in northern Australia, 252 cases were found over 10 years. Of these, 46% were bacteremic, and 49 (19%) patients died. Despite administration of ceftazidime or carbapenems, mortality was 86% (43 of 50 patients) among those with septic shock. Pneumonia accounted for 127 presentations (50%) and genitourinary infections for 37 (15%), with 35 men (18%) having prostatic abscesses. Other presentations included skin abscesses (32 patients; 13%), osteomyelitis and/or septic arthritis (9; 4%), soft tissue abscesses (10; 4%), and encephalomyelitis (10; 4%). Risk factors included diabetes (37%), excessive alcohol intake (39%), chronic lung disease (27%), chronic renal disease (10%), and consumption of kava (8%). Only 1 death occurred among the 51 patients (20%) with no risk factors (relative risk, 0.08; 95% confidence interval, 0.01-0.58). Intensive therapy with ceftazidime or carbapenems, followed by at least 3 months of eradication therapy with trimethoprim-sulfamethoxazole, was associated with decreased mortality. Strategies are needed to decrease the high mortality with melioidosis septic shock. Preliminary data on granulocyte colony-stimulating factor therapy are very encouraging.

          Related collections

          Author and article information


          Comment on this article